Innovation and Product Development news (page 2)

• 

  3 August 2026

  Eli Lilly: olomorasib receives FDA Breakthrough Therapy for previously treated KRAS G12C advanced pancreatic cancer

  Breakthrough designation covers olomorasib monotherapy for adults with advanced pancreatic cancer harboring KRAS G12C after at least one prior systemic therapy.
• 

  3 August 2026

  Mitsubishi Gas Chemical and Veritas In Silico file patent for nucleic acid drug targeting lncRNA H19

  Patent application covers a nucleic acid therapeutic against lncRNA H19 developed with an AI-driven discovery platform; commercialization planned using dedicated CRDMO capacity.
• 

  3 August 2026

  CPPC and SCGC launch ASEAN’s first food-grade recycled pet food packaging

  Food-grade recycled pet food packaging uses advanced recycling to convert post-consumer plastics into certified circular polyolefins, ISCC PLUS certified and commercial since 2024.
• 

  31 July 2026

  Sasol and partners commission 2 kW HySA PEM electrolyser in Sasolburg

  A 2 kW PEM electrolyser will be used for testing, skills development and system integration under variable renewable power, supporting localisation and PGM beneficiation.
• 

  31 July 2026

  Novo Nordisk: ZEUS phase 3 finds no MACE reduction with ziltivekimab

  Ziltivekimab lowered free IL‑6 and hsCRP but did not reduce cardiovascular events; safety similar to placebo except for more serious infections; related trials continue with H1 2027 readouts.
• 

  31 July 2026

  Moeve H1 2026: €1.2bn Clean CCS EBITDA; 69% of H1 capex to energy transition in Spain

  Net income €458m, capex €605m and operating cash flow €762m; leverage fell to 1.2x; groundbreaking for 300 MW Andalusian Green Hydrogen Valley on Sept 17; Galp merger talks continue.

• 

  31 July 2026

  Chugai files for Enspryng indication to prevent relapses in MOGAD in Japan

  Regulatory submission seeks approval of satralizumab to prevent relapse in MOG antibody‑associated disease after Phase III showed a 68% risk reduction.
• 

  31 July 2026

  OMV Petrom Group H1 2026 results

  Clean CCS Operating Result 3 bn lei; net income 1.8 bn lei; CAPEX 3.7 bn lei; contribution to state budget 10.2 bn lei; Neptun Deep on track for first gas in 2027.
• 

  31 July 2026

  Umicore H1 2026 results

  Adj. EBITDA +33% to €577m and margin 30.2%; revenues €1.9bn; Free Operating Cash Flow €295m; guidance upgraded to slightly above €1bn adj. EBITDA for FY2026.
• 

  31 July 2026

  Clariant Q2 2026: margins improve and Amsterdam court dismisses Shell ethylene claim

  Q2 comparable sales roughly flat; EBITDA margin up 80bp; performance-savings target raised to CHF100m; Amsterdam court dismissed Shell and Stichting Ethylene Claims suits.
• 

  31 July 2026

  Linde to invest $1 billion in Phoenix on-site gases complex for semiconductor expansion

  Expands on-site gases capacity in Phoenix for two new fabs; adds two SPECTRA ASUs to supply ultra-high-purity N2, O2 and Ar; JV to invest ~$800M in Taiwan.
• 

  30 July 2026

  Johnson & Johnson: FDA Priority Review for potential first-in-class subcutaneous RYBREVANT FASPRO in recurrent/metastatic HNSCC

  OrigAMI-4 showed 42% response rate with >1/3 complete responses; FDA review shortened to ~6 months; drug targets EGFR and MET and is co-formulated with hyaluronidase.
• 

  30 July 2026

  BASF: Mix of technologies required to recycle engineering plastics

  Engineering plastics need tailored recycling—mechanical, solvent, depolymerisation or thermochemical—selected by waste composition; loopamid commercial plant began in early 2025; sorting and regulation are crucial.
• 

  30 July 2026

  Takeda Q1 FY2026 results and ORZEYFUL China approval

  Solid quarter: revenue +10.2% AER; adjusted free cash flow JPY 68.6bn; launch prep for ORZEYFUL, rusfertide and zasocitinib; FY2026 outlook unchanged.
• 

  30 July 2026

  Symrise H1 2026: €2.54bn sales as Q2 organic growth accelerates

  Organic growth accelerated to 4.5% in Q2; H1 sales €2.54bn, adjusted EBITDA margin 21.8%, offer for Floral Concept and ONE SYM transformation accelerated.
• 

  30 July 2026

  Evonik‑licensed Leshan H₂O₂ megaplant (Fuhua) starts production

  200 kt/yr industrial H₂O₂ plant began operations on 18 June 2026; will sell to the merchant market and supply a JV for further purification into specialty grades.
• 

  29 July 2026

  SABIC Q2 2026 revenue $6.62bn; earnings fall

  Q2 sales fell 5% Q-o-Q; adjusted EBITDA SAR 3.38bn; H1 dividend SAR 3.3bn; Fujian complex start-up expected Q4 2026.
• 

  29 July 2026

  Johnson & Johnson completes $1 billion acquisition of Firefly Bio

  Adds Firelink™ degrader antibody conjugate platform to target pan‑KRAS and other hard‑to‑treat solid tumors; transaction carries near‑term R&D charge and EPS dilution.
• 

  29 July 2026

  Johnson & Johnson partners with Sail Biomedicines on in vivo CAR‑T with $2.58B acquisition option

  Advance lead in vivo CAR‑T program to reset the immune system for immune‑mediated disease; $785M initial funding, $140M milestones, and a $2.58B acquisition option.
• 

  29 July 2026

  ViiV Healthcare: Cabenuva superior to daily oral therapy in adolescents at AIDS 2026

  LATA shows superiority in adolescents; OPERA real‑world suppression comparable to oral regimens; cabotegravir injections rated better than lenacapavir; EXTEND 4M tests 4‑month formulation.
• 

  29 July 2026

  Brenntag and Budenheim partner on BYPHAR biopharma phosphates

  Co-branded GMP phosphates offered in ≤15 kg biopharma packs globally; original product line distributed in ≥25 kg packs across Europe.
• 

  28 July 2026

  Toray develops resin-film substrate for anode current collectors

  Resin-film substrate for anode current collectors matches copper performance, cuts collector weight 50–60%, reduces cell weight ≈10%, produced at 4.5 µm and sampled to customers.
• 

  28 July 2026

  Petrobras Q2 2026 own production reaches 3.34 MMboed

  Record oil, NGL and gas output reached 3.34 MMboed in Q2, up 14.1% YoY; operated production 4.87 MMboed; refinery utilisation 101.2% and derivative imports at pandemic-low.
• 

  28 July 2026

  Eastman and University of Tennessee extend research partnership through 2032

  Six-year master research agreement includes at least $3 million in funding for sponsored projects, service agreements, student programs and on‑campus collaboration.
• 

  28 July 2026

  GSK to open flagship R&D centre on Cambridge Biomedical Campus

  New 300,000 sq ft centre will house 1,000+ scientists, focusing on oncology, respiratory, hepatology, vaccines and HIV; £400m UK investment and Stevenage move by 2029.
• 

  28 July 2026

  GSK Q2: strong core results, R&D acceleration and 20+ Phase III starts in 2026

  Core operating profit +7% and core EPS +9%; sales up, driven by Specialty Medicines and Vaccines; new R&D centre and a 3-year £1.9bn annual savings target to fund late-stage pipeline.
• 

  28 July 2026

  Hansoh Pharma/GSK: Ris‑Rez meets PFS endpoint in China phase III ARTEMIS‑011 (relapsed osteosarcoma)

  ARTEMIS‑011 showed significant PFS benefit versus chemotherapy in relapsed osteosarcoma after ≥2 prior therapies; OS benefit and expected safety observed; data to support Chinese submission.
• 

  28 July 2026

  Volkswagen fits ID. Buzz spoilers with PLEXIGLAS® (Röhm) Piano Black mold‑in‑color PMMA

  Mold‑in‑color PMMA removes coating, cutting VOCs, energy and water use; delivers Class A glossy, UV‑ and chemical‑resistant exterior parts produced with 2C injection‑compression.
• 

  28 July 2026

  Croda H1 2026 results: £880.5m sales and margin progress from transformation

  Group organic sales +4.6% in H1; adjusted operating profit £155.8m; free cash flow up 36.8%; FY26 guidance unchanged with 3–6% organic range.
• 

  28 July 2026

  Air Liquide H1 2026: near €14bn revenue with Q2 acceleration

  Second-quarter comparable growth accelerated; operating margin, recurring profit and cash flow improved while record investments and the DIG Airgas deal closed.